Acorda Therapeutics

Acorda Therapeutics is a biopharmaceutical company focused on developing therapies for neurological disorders. The company's marketed therapies include: Ampyra, an extended release tablet formulation of dalfampridine for the treatment of multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. The company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease and MS. The company's research and development program include SYN120, which is a potential treatment for Parkinson's-related dementia; and BTT1023 (timolumab), a product candidate for the orphan disease Primary Sclerosing Cholangitis.
  • TickerACOR
  • ISINUS00484M1062
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Laura Chico

ACOR_20190716

Wedbush Research

Wedbush Morning Call - Jul 16 2019 6:50AM

Laura Chico

Ahead of 2Q19 Biotech Reporting - Thoughts on Commercial Names

ValuEngine Rating and Forecast Report for ACOR

ValuEngine Rating and Forecast Report for ACOR

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Laura Chico

ACOR_20190716

Wedbush Research

Wedbush Morning Call - Jul 16 2019 6:50AM

Laura Chico

Ahead of 2Q19 Biotech Reporting - Thoughts on Commercial Names

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for ACOR

ValuEngine Rating and Forecast Report for ACOR

ValuEngine Rating and Forecast Report for ACOR

ValuEngine Rating and Forecast Report for ACOR

ValuEngine Rating and Forecast Report for ACOR

ValuEngine Rating and Forecast Report for ACOR

ValuEngine Rating and Forecast Report for ACOR

ValuEngine Rating and Forecast Report for ACOR

Due to a more favourable environment, ACORDA THERP.INCO. slightly increases to Slightly Negative

ACORDA THERP.INCO. (US), a company active in the Biotechnology industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date June 18, 2019, the closing price was USD 7.66 and its target price was estimated at USD 6.57.

MarketLine Department

Cancer Genetics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Cancer Genetics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Cancer Genetics, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advanta...

MarketLine Department

ARCA biopharma, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's ARCA biopharma, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by ARCA biopharma, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantag...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Biotechs are breaking out. XBI and IBB ETF's are bullish. • Homebuilders appear to be staging near-term reversals in price and RS. • Railroads continue to lead in the Transportation Sector. Many truckers are reversing near-term downtrends. • A few Consumer Staples equities are staging price and RS reversals. (Example POST)

Dave Nicoski

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

Shelley Moen

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

Shelley Moen

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch